后天抵抗
蛋白激酶结构域
医学
肺癌
原癌基因蛋白质c-ret
激酶
癌症研究
生物信息学
肿瘤科
内科学
癌症
生物
基因
遗传学
受体
突变体
神经营养因子
胶质细胞源性神经生长因子
作者
Jessica J. Lin,Justin F. Gainor
标识
DOI:10.1038/s41416-021-01344-7
摘要
Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, in most cases, due to RET-independent mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI